more

Client Profile

Thermalin Diabetes, Inc.

Based in Cleveland and built on technology developed by Dr. Michael A. Weiss at Case Western Reserve Medical School, Thermalin Diabetes, LLC is developing clinically-superior, second generation, insulin analogs for the rapidly-growing $12 billion insulin market. Themalin's patent pending compounds include rapid-, intermediate - and long-acting analogs. For more information, please contact Richard Berenson(rick@thermlin.com).

CEO
Richard Berenson
Type of Business
Biotech
Number of Employees
7
Recent Successes
Closed a $2.85 million Series A investment round.